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Background: Several genetic polymorphisms have been reported to modify the effects of smoking on serum lipid
levels. The objective of this study was to investigate whether longevity-associated mitochondrial DNA 5178
(Mt5178) C/A polymorphism modifies the effects of habitual smoking on the risk of dyslipidemia in middle-aged
Japanese subjects.
Methods: A total of 394 male subjects (age, 53.9 ± 7.9 years; mean ± SD) were selected from among individuals
visiting the hospital for regular medical check-ups. After Mt5178 C/A genotyping, a cross-sectional study assessing
the joint effect of Mt5178 C/A polymorphism and cigarette smoking on the risk of hypo-high-density lipoprotein
(HDL) cholesterolemia, hyper-low-density lipoprotein (LDL) cholesterolemia or hypertriglyceridemia was conducted.
Results: For subjects with Mt5178C, the risk of hypo-HDL cholesterolemia increased with the number of cigarettes
smoked daily (P for trend = 0.001). On the other hand, the association between Mt5178A genotype and the risk
of hypo-HDL cholesterolemia did not appear to depend on the number of cigarettes smoked daily. For those
with Mt5178A, the risk of hyper-LDL cholesterolemia or hypertriglyceridemia increased with cigarettes smoked daily
(P for trend = 0.017 and P for trend = 0.002, respectively). However, the association between Mt5178C genotype
and the risk of hyper-LDL cholesterolemia or hypertriglyceridemia did not depend on the number of cigarettes
smoked daily.
Conclusions: The present results suggest that Mt5178 C/A polymorphism modulates the effects of habitual
smoking on the risk of dyslipidemia in middle-aged Japanese men.
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Prevention of Coronary heart disease (CHD) is one of the
major public health issues. The Global Burden of Disease
Study showed that CHD is predicted as the leading cause
of death not only in 1990 but also in 2020 [1]. Population-
based follow-up studies showed that smoking is one of
critical risk factors of CHD [2,3]. Cigarette smoking is
assumed to be involved in vasomotor dysfunction, inflam-
mation and modification of lipids, which are the compo-
nents for atherogenesis [4]. Habitual smoking promotes
detrimental changes in serum lipid profile. From analysis
of published data, Craig et al. concluded that habitual
smoking is associated with significantly lower serum high-
density lipoprotein (HDL) cholesterol levels, and higher
serum low-density lipoprotein (LDL) cholesterol levels and
serum triglyceride levels [5]. However, from a cross-
sectional and longitudinal analysis in a large Japanese co-
hort, Kuzuya et al. reported that serum LDL cholesterol
levels are significantly lower in smokers than in non-
smokers [6]. One of the reasons for these inconsistent
results may be differences in genetic background.
Several genetic polymorphisms have been reported to in-
fluence the effect of smoking on lipid profiles [7-12]. One
of these polymorphisms is mitochondrial DNA cytosine/
adenine (Mt5178 C/A) polymorphism, which is also recog-
nized as NADH dehydrogenase subunit-2 237 leucine/
methionine (ND2-237 Leu/Met) polymorphism. The fre-
quency of the Mt5178A genotype is significantly higher in
Japanese centenarians than in the general population, thus
Mt5178 C/A polymorphism is associated with longevity
in Japanese [13]. Moreover, from clinical points of view,
Japanese individuals with Mt5178A are more resistant to
adult-onset lifestyle-related diseases, such as hypertension
[14], diabetes [15], myocardial infarction [16,17] and cere-
brovascular disorders [18], than those with Mt5178C. This
longevity-associated Mt5178 C/A polymorphism subclini-
cally influences the effects of habitual smoking on serum
concentration of triglyceride [12]. Recently, this poly-
morphism is reported to modify the effects of alcohol con-
sumption [19] or coffee intake [20] on the risk of
dyslipidemia. These previous studies stimulated our clinical
interests to investigate whether there is a combined effects
of Mt5178 C/A polymorphism and habitual smoking on
the risk of dyslipidemia or not.
This study aims to investigate whether longevity-
associated Mt5178 C/A polymorphism modifies the
effects of habitual smoking on the risk of hypo-HDL
cholesterolemia, hyper-LDL cholesterolemia or hypertri-
glyceridemia in middle-aged Japanese male subjects.
Subjects and methods
Subjects
Participants were recruited from among individuals visit-
ing the Mito Red Cross Hospital for regular medicalcheck-ups between August 1999 and August 2000. This
study was conducted in accordance with the Declaration
of Helsinki and was approved by the Ethics Committee
of the Kyorin University School of Medicine. Written
informed consent was obtained from 602 volunteers be-
fore participation. Because the number of women was
insufficient for classification into groups based on
Mt5178 C/A genotype and smoking status, women were
excluded. Patients taking antihyperlipidemic medication
were excluded, and diabetic patients were also excluded
because of the higher prevalence of dyslipidemia in dia-
betic patients when compared to non-diabetic patients
[21]. Thus, 406 men were enrolled in the study. Twelve
individuals with unclear data were also excluded. There-
fore, subjects comprised 394 Japanese men (age,
53.9 ± 7.9 years; mean ± SD).
Clinical characteristics of subjects
Determination of blood chemical and physical data
was conducted as described previously [22]. Accord-
ing to the Japan Atherosclerosis Society guidelines
for prevention of atherosclerotic cardiovascular dis-
eases [23], hyper-LDL cholesterolemia as serum LDL
cholesterol ≥ 140 mg/dl, hypo-HDL cholesterolemia as
serum HDL cholesterol < 40 mg/dl and hypertriglyceride-
mia was defined as serum triglyceride ≥ 150 mg/dl. Body
mass index (BMI) was defined as the ratio of subject
weight (kg) to the square of subject height (m). LDL chol-
esterol levels were calculated by means of Friedewald’s
formula [24]. A survey of habitual smoking, alcohol con-
sumption and coffee consumption was performed by
means of questionnaire. Smoking status was classified
based on number of cigarettes smoked per day (never-
or ex-smokers; 1–20 cigarettes smoked per day; and
>20 cigarettes smoked per day). Alcohol consumption
was classified based on drinking frequency (daily drin-
kers; occasional drinkers, which include those who drink
several times per week or per month; and non- or ex-
drinkers). Coffee consumption was classified based on
number of cups of coffee per day (≤1 cup per day; 2–3
cups per day; and ≥4 cups per day). For use of antihyper-
tensive medication, subjects were classified as taking no
drug treatment or taking medicine.
Genotyping
DNA was extracted from white blood cells using the
DNA Extractor WB kit (Wako Pure Chemical Industries,
Japan). The Mt5178 C/A polymorphism was detected by
polymerase chain reaction (PCR) and digestion with
AluI restriction enzyme. The sequence of primers
was: forward 5’-CTTAGCATACTCCTCAATTACCC-3’,
reverse 5’-GTGAATTCTTCGATAATGGCCCA-3’. The
PCR was performed with 50 ng genomic DNA in buffer
containing 0.2 μmol/l of each primer, 1.25 mmol/l
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merase. After an initial denaturation at 94°C for 5 min,
PCR was conducted through 40 cycles in the following
steps: denaturation at 94°C for 30 s, annealing at 60°C
for 60 s and polymerase extension at 72°C for 90 s. After
cycling, a final extension at 72°C for 10 min was per-
formed. The PCR products were digested with AluI re-
striction enzyme (Nippon Gene, Japan) at 37°C
overnight, and electrophoresed in 1.5% agarose gels
stained with ethidium bromide for visualization under
ultraviolet light. The absence of an AluI site was desig-
nated as Mt5178A, and the presence of this restriction
site was designated as Mt5178C.
Statistical analyses
Statistical analyses were performed using SAS statistical
software, version 9.2 for Windows. Multiple logistic
regression analysis was used to calculate odds ratios
(OR) for hypo-HDL cholesterolemia, hyper-LDL cho-
lesterolemia or hypertriglyceridemia. For multiple logis-
tic regression analysis and analysis of covariance,
habitual alcohol consumption (non- or ex- drinkers = 0,
occasional- drinkers = 1, daily- drinkers = 2), coffee con-
sumption (≤1 cup per day = 1, 2–3 cups per day = 2, ≥4
cups per day = 3) and antihypetensive medication use
(no use of antihypetensive = 0, use of antihypetensive = 1)
were numerically coded. Differences with P values of less
than 0.05 were considered to be statistically significant.
Results
No significant differences in biophysical or biochemical
characteristics were observed between the Mt5178C and
Mt5178A genotypes (Table 1). No significant differences
in smoking status were observed between the Mt5178
C/A genotypes. From viewpoints of dyslipidemia, no
significant differences in the frequency of hypo-HDL
cholesterolemia, that of hyper-LDL cholesterolemia or
that of hypertriglyceridemia were observed between men
with Mt5178C and those with Mt5178A.
For Mt5178C genotypic men, after adjustment for age
and BMI or for age, BMI, alcohol consumption, coffee
consumption and use of antihypertensive medication,
number of cigarettes smoked per day was negatively and
significantly associated with serum HDL cholesterol
levels (adjusted P for trend = 0.008 and adjusted P for
trend = 0.037, respectively) (Table 2). For Mt5178A
genotypic men, this negative association between num-
ber of daily cigarettes smoked and serum HDL levels did
not reach to significant level. However, for Mt5178A
genotypic men, number of cigarettes smoked per day
was positively and significantly associated with serum
triglyceride levels (P for trend < 0.001). After adjustment,
this positive association between number of cigarette
consumed per day and serum triglyceride levels remainedsignificant level. Moreover, after adjustment or not,
serum triglyceride levels were significantly higher in
those who consumed >20 cigarettes per day than in
never- or ex-smokers or in subjects who consumed 1–20
cigarettes per day (P < 0.001 and P < 0.001, respectively).
For subjects with Mt5178C, the risk of hypo-HDL
cholesterolemia may depend on number of daily cigar-
ettes smoked (P for trend = 0.001) (Table 3). After adjust-
ment, positive association between increasing number of
daily cigarettes smoked and the risk of hypo-HDL cho-
lesterolemia remained significantly. The crude OR for
hypo-HDL cholesterolemia was significantly higher in
subjects who consumed 1–20 cigarettes per day or
in those who consumed >20 cigarettes per day than in
never- or ex-smokers (OR= 3.058, 95% confidence inter-
val (CI): 1.221–7.654, P= 0.017 and OR= 5.172, 95% CI:
1.732–15.44, P= 0.003, respectively). After adjustment
for age and BMI or for age, BMI, habitual alcohol con-
sumption, coffee consumption and use of antihyperten-
sive medication, a significant OR remained. On the
other hand, the association between Mt5178A genotype
and the risk of hypo-HDL cholesterolemia does not ap-
pear to depend on number of daily cigarettes smoked.
For subjects with Mt5178A, the risk of hyper-LDL
cholesterolemia may depend on number of daily cigar-
ettes smoked (P for trend = 0.017) (Table 4). After adjust-
ment, increasing daily cigarettes smoked of the risk of
hyper-LDL cholesterolemia remained significantl level.
The crude OR for hyper-LDL cholesterolemia was sig-
nificantly higher in subjects who consumed 1–20 cigar-
ettes per day or in those who consumed >20 cigarettes
per day than in never- or ex-smokers (OR= 2.376, 95%
CI: 1.029–5.482, P= 0.043 and OR= 2.836, 95% CI:
1.055–7.626, P= 0.039, respectively). After adjustment, a
OR remained significant. For them, the risk of hypertri-
glyceridemia may also depend on number of daily cigar-
ettes smoked (P for trend = 0.002) (Table 5). After
adjustment, increasing daily cigarettes smoked of the
risk of hypertriglyceridemia remained significant. The
crude OR for hypertriglyceridemia was significantly
higher in subjects who consumed >20 cigarettes per day
than in never- or ex-smokers (OR= 5.966, 95% CI:
2.233–15.90, P<0.001). After adjustment, a significant OR
remains. On the other hand, the association between
Mt5178C genotype and the risk of hyper-LDL cholestero-
lemia or that of hypertriglyceridemia does not seem to de-
pend on number of daily cigarettes smoked (Tables 4, 5).
Discussion
In the present study, we observed that longevity-
associated Mt5178 C/A polymorphism may influence
the effects of habitual smoking on increasing the risk of
hypo-HDL cholesterolemia, that of hyper-LDL cholester-
olemia or that of hypertriglyceridemia in middle-aged
Table 1 Clinical characteristics of study subjects by Mt5178 C/A genotype
Mt5178C Mt5178A P value
N=239 N=155
Age (y) 54.3 ± 7.8 53.2 ± 7.8 0.171
Body Mass Index (kg/m2) 23.3 ± 2.8 23.5 ± 2.6 0.461
Serum total cholesterol (mg/dl) 203.5 ± 34.3 202.1 ± 31.8 0.672
Serum HDL cholesterol (mg/dl) 54.6 ± 13.6 56.3 ± 16.2 0.269
Serum LDL cholesterol (mg/dl) 121.6 ± 34.8 117.9 ± 30.5 0.281
Serum Triglyceride (mg/dl) 136.7 ± 91.1 139.5 ± 90.8 0.766
Systolic blood pressure (mmHg) 125.8 ± 15.9 125.7 ± 14.1 0.940
Diastolic blood pressure (mmHg) 74.0 ± 10.7 73.8 ± 9.1 0.823
Fasting plasma glucose (mg/dl) 97.2 ± 9.4 97.6 ± 9.7 0.672
Smoking status (never- or ex-/ 1–20 cigarettes per day/ >20 cigarettes per day) (%) 59.4/29.7/10.9 59.4/25.8/14.8 0.429
Alcohol consumption (daily/occasionally/non- or ex-) (%) 46.4/35.2/18.4 47.7/38.7/13.6 0.426
Coffee consumption (≤ 1 cup per day/2-3 cups per day/≥ 4 cups per day) (%) 61.1/29.7/9.2 55.5/32.9/11.6 0.510
Antihypertensive medication use (%) 18.8 12.9 0.122
Hypo-HDL cholesterolemia (%) 11.7 12.3 0.871
Hyper-LDL cholesterolemia (%) 26.4 25.8 0.903
Hypertriglyceridemia (%) 29.7 29.7 0.995
HDL; high-density lipoprotein. LDL; low-density lipoprotein. Age, body mass index, serum HDL cholesterol levels, serum LDL cholesterol levels, serum triglyceride
levels, systolic blood pressure, diastolic blood pressure, fasting plasma glucose levels are given as means ± S.D. For smoking status, coffee consumption, alcohol
consumption, antihypertensive medication use, hypo-HDL cholesterolemia, hyper-LDL cholesterolemia and hypertriglyceridemia, P values were calculated by chi-
squared test. All P values depict significance of differences between Mt5178C and Mt5178A.
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ceptible to atherosclerotic diseases than those with
Mt5178A, habitual smoking may increase the risk of hypo-
HDL cholesterolemia. On the other hand, for men with
Mt5178A, cigarette smoking may increase the risk of
hyper-LDL cholesterolemia or that of hypertriglyceridemia.
These findings are new gene-environment interactions on
the risk of dyslipidemia and may contribute to establish-
ment of individualized prevention for dyslipidemia.
Meta-analysis conducted by Craig et al. showed that
smokers have significantly lower serum HDL cholesterol
levels, and higher serum LDL cholesterol levels and serum
triglyceride levels [5]. However, the large-scale cross-sec-
tional and longitudinal analysis showed that serum LDL
cholesterol levels in smokers are significantly lower than
those in non-smokers [6]. Genetic epidemiological
approaches may be useful for elucidating this inconsistency
in the effects of habitual smoking on serum lipid profiles.
In addition to our results, several joint effects of genetic
factor and cigarette smoking on HDL cholesterol levels [7-
10], LDL cholesterol levels [9] or triglyceride levels [11,12]
have been already published. The polymorphism in
PNPN11 gene, encoding Src homology 2 domain-
containing protein tyrosine phosphatase-2, modulates the
effect of cigarette smoking on serum HDL cholesterol
levels and serum LDL cholesterol levels [9]. Among the
PTPN11 (rs2301756) AA genotype, asignificant increase in
HDL cholesterol levels and a significant decrease in LDLcholesterol levels in current smokers compared to non-
smokers [9]. Moreover, more than twenty genetic variants
are reported to be associated with modulated lipid levels,
and some of them are also associated with the risk of CHD
[25]. Therefore, these reports and our results inspire to in-
vestigate gene-gene or gene-gene-environment interac-
tions, for example lipoprotein lipase gene-apolipoprotein
C-III gene-smoking interaction [7], on serum lipids levels,
the risk of dyslipidemia or that of CHD.
For men with Mt5178C, habitual smoking may signifi-
cantly decrease the serum HDL cholesterol levels and
significantly increase the risk of hypo-HDL cholesterole-
mia. For those with Mt5178A, habitual smoking may
significantly increase both the serum triglyceride levels
and the risk of hypertriglyceridemia. In these observa-
tions, joint effects of Mt5178 C/A polymorphism and
habitual smoking on the risk of dyslipidemia are consist-
ent with those on serum lipid profiles. However, for men
with Mt5178A, cigarette smoking may not significantly
increase the serum LDL cholesterol levels but may sig-
nificantly increase the risk of hyper-LDL cholesterole-
mia. Originally, diagnostic criteria for dislipidemia,
namely hyper-LDL cholesterolemia, hypo-HDL choles-
terolemia and hypertriglyceridemia, was proposed for
the prevention of atherosclerotic diseases, especially
CHD [23]. From viewpoints of preventive medicine, de-
tection of the genetic risk for dyslipidemia is more clin-
ically important than that of genetic factors influencing
Table 2 Serum lipid levels among three smoking status by Mt5178 C/A genotypes
Smoking status P for trend
Never- or ex-smokers 1-20 cigarettes smoked per day >20 cigarettes smoked per day
Mt5178C N= 142 N= 70 N= 27
HDL cholesterol 55.9 ± 1.1 52.6 ± 1.6 52.6 ± 2.6 0.089
HDL cholesterol † 56.5 ± 1.1 52.1 ± 1.5 51.0 ± 2.5 0.008
HDL cholesterol { 55.6 ± 1.6 52.2 ± 1.8 51.1 ± 2.7 0.037
LDL cholesterol ‡ 122.2 ± 2.9 116.8 ± 4.1 130.7 ± 6.7 0.672
LDL cholesterol † 121.8 ± 2.9 117.2 ± 4.2 131.9 ± 6.8 0.514
LDL cholesterol ‡ 126.7 ± 4.5 119.7 ± 5.0 134.6 ± 7.4 0.795
Triglyceride 134.7 ± 7.7 139.6 ± 10.9 139.5 ± 17.6 0.717
Triglyceride† 133.3 ± 7.5 141.0 ± 10.7 143.2 ± 17.3 0.502
Triglyceride{ 125.6 ± 11.6 135.8 ± 13.0 138.5 ± 19.3 0.394
Mt5178A N= 92 N= 40 N= 23
HDL cholesterol 57.5 ± 1.7 56.2 ± 2.6 51.5 ± 3.4 0.136
HDL cholesterol † 58.0 ± 1.6 54.1 ± 2.5 53.0 ± 3.2 0.100
HDL cholesterol { 56.3 ± 2.6 52.1 ± 2.9 50.7 ± 3.8 0.071
LDL cholesterol 115.8 ± 3.2 119.6 ± 4.8 123.2 ± 6.4 0.266
LDL cholesterol † 115.1 ± 3.2 122.1 ± 4.9 121.8 ± 6.3 0.221
LDL cholesterol { 118.3 ± 5.1 122.6 ± 5.8 123.3 ± 7.6 0.392
Triglyceride 120.4 ± 8.6 130.9 ± 13.1 230.7 ± 17.3*,** <0.001
Triglyceride† 119.4 ± 8.5 136.8 ± 13.1 224.6 ± 17.0*,** <0.001
Triglyceride{ 114.5 ± 13.6 137.4 ± 15.4 223.5 ± 20.4*,** <0.001
HDL; high-density lipoprotein. LDL; low-density lipoprotein. †HDL cholesterol levels, †LDL cholesterol levels and †triglyceride levels are given as least-square
mean ± S.E. adjusted for age, body mass index; {HDL cholesterol levels , ‡LDL cholesterol levels and ‡triglyceride levels are given as least-square mean ± S.E.
adjusted for age, body mass index, alcohol consumption, coffee consumption and antihypertensive medication use. The Bonferroni correction for multiple
comparison was applied. *P< 0.001 vs. never- or ex-smokers, **P< 0.001 vs. current smokers who smoked 1–20 cigarettes per day.
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Mt5178 C/A genotype is thought to be practical.
Our previous investigations revealed that daily consump-
tion of≥ 1 cup of coffee may increase the risk of hyper-LDL
cholesterolemia for Mt5178A genotypic men [20]. Clinically
interestingly, daily alcohol consumption may reduce the
risk of hyper-LDL cholesterolemia for men with Mt5178C
[19] and decrease serum triglyceride levels for those with
Mt5178A [12]. Makita et al. reported that yearly changes in
serum LDL cholesterol levels were significantly lower in
non-daily drinkers with Mt5178A than in those with
Mt5178C [26]. Therefore, the determination of Mt5178 C/
A genotypes seems productive of establishing individualized
prevention of dyslipidemia. Moreover, based on the infor-
mation of Mt5178 C/A polymorphism, personalized behav-
ior modifications in lifestyle, namely smoking cessation,
possibly contribute to establishing personalized prevention
for hypo-HDL cholesterolemia among Mt5178C genotypic
men, for hyper-LDL cholesterolemia or that of hypertrigly-
ceridemia among Mt5178A genotypic men and then for
subsequent life-threatening atherosclerotic diseases among
the both genotypic men. Actually, the meta-analysis showed
that smoking cessation increases HDL cholesterol level[27]. However, Yoon et al. disclosed that smoking
cessation-associated harmful changes in the risk factors for
CHD were predominantly secondary to weight gain, and
advocated attentive weight control in smoking quitters in
order to reduce the risk of CHD [28].
The mechanism underlying the combined effects of
Mt5178 C/A polymorphism and habitual smoking on the
risk of dyslipidemia has not been elucidated. Individuals
with the Mt5178A genotype are more resistant to athero-
sclerotic diseases than those with the Mt5178C genotype
[16-18]. These antiatherogenic advantages are presumed to
be brought from the biophysical and biochemical properties
of ND2-237Met, which is genetically coded by Mt5178A.
NADH dehydrogenase, namely respiratory chain complex
I, is considered as the major physiological and pathological
site of reactive oxygen species (ROS) generation in mito-
chondria, and as a target of attack by ROS [29]. Mitochon-
drial DNA is also vulnerable to damage by ROS [29].
Increased mitochondrial ROS production, mitochondrial
dysfunction and mitochondrial DNA mutation are asso-
ciated with atherosclerotic diseases [29]. Mouse mitochon-
drial DNA 4738 C/A (Mt4738 C/A) polymorphism also
results in a leucine to methionine substitution in NADH
Table 3 Odds ratios (ORs) and 95% confidence intervals (CIs) for hypo-HDL cholesterolemia by Mt5178 C/A genotype and smoking status
Genotype and number







cholesterol (HDL cholesterol≥ 40 mg/dl)
Hypo-HDL
cholesterolemia (HDL cholesterol < 40 mg/dl)
Mt5178C
0 (never- or ex-smoker) 133 (93.7) 9 (6.3) 1 (reference) 1 (reference) 1 (reference)
1-20 58 (82.9) 12 (17.1) 3.058 (1.221-7.654)* 3.317 (1.303-8.446)* 2.771 (1.039-7.388)*
>20 20 (74.1) 7 (25.9) 5.172 (1.732-15.44)** 8.048 (2.244-28.87)** 8.339 (1.993-34.89)**
P for trend = 0.001 P for trend< 0.001 P for trend= 0.002
Mt5178A
0 (never- or ex-smoker) 82 (89.1) 10 (10.9) 1 (reference) 1 (reference) 1 (reference)
1-20 34 (85.0) 6 (15.0) 1.447 (0.488-4.297) 2.143 (0.664-6.918) 1.703 (0.481-6.027)
>20 20 (87.0) 3 (13.0) 1.230 (0.310-4.888) 1.158 (0.281-4.781) 1.264 (0.289-5.533)
P for trend = 0.629 P for trend= 0.563 P for trend= 0.577
†OR adjusted for age and body mass index.
{OR adjusted for age, body mass index, habitual alcohol consumption, coffee consumption and antihypertensive medication.
*P< 0.05, **P< 0.005.
Table 4 Odds ratios (ORs) and 95% confidence intervals (CIs) for hyper-LDL cholesterolemia by Mt5178 C/A genotype and smoking status
Genotype and number







cholesterol (LDL cholesterol < 140 mg/dl)
Hyper-LDL
cholesterolemia (LDL cholesterol≥ 140 mg/dl)
Mt5178C
0 (never- or ex-smoker) 107 (75.4) 35 (24.6) 1 (reference) 1 (reference) 1 (reference)
1-20 53 (75.7) 17 (24.3) 0.981 (0.504-1.910) 0.972 (0.492-1.923) 0.944 (0.460-1.940)
>20 16 (59.3) 11 (40.7) 2.102 (0.892-4.953) 2.181 (0.889-5.348) 2.506 (0.973-6.457)
P for trend = 0.181 P for trend= 0.160 P for trend = 0.164
Mt5178A
0 (never- or ex-smoker) 75 (81.5) 17 (18.5) 1 (reference) 1 (reference) 1 (reference)
1-20 26 (65.0) 14 (35.0) 2.376 (1.029-5.482)* 2.993 (1.222-7.330)* 2.790 (1.080-7.206)*
>20 14 (60.9) 9 (39.1) 2.836 (1.055-7.626)* 2.982 (1.080-8.232)* 2.908 (1.012-8.351)*
P for trend = 0.017 P for trend= 0.014 P for trend = 0.035
†OR adjusted for age and body mass index.
{OR adjusted for age, body mass index, habitual alcohol consumption, coffee consumption and antihypertensive medication.





















Table 5 Odds ratios (ORs) and 95% confidence intervals (CIs) for hypertriglyceridemia by Mt5178 C/A genotype and smoking status
Genotype and number






(95% CI)Normal triglyceride level




0 (never- or ex-smoker) 102 (71.8) 40 (28.2) 1 (reference) 1 (reference) 1 (reference)
1-20 48 (68.6) 22 (31.4) 1.169 (0.627-2.180) 1.226 (0.640-2.350) 1.355 (0.681-2.697)
>20 18 (66.7) 9 (33.3) 1.275 (0.529-3.073) 1.429 (0.563-3.631) 1.517 (0.575-3.998)
P for trend = 0.517 P for trend = 0.366 P for trend= 0.282
Mt5178A
0 (never- or ex-smoker) 70 (76.1) 22 (23.9) 1 (reference) 1 (reference) 1 (reference)
1-20 31 (77.5) 9 (22.5) 0.924 (0.382-2.234) 1.261 (0.485-3.284) 1.588 (0.537-4.697)
>20 8 (34.8) 15 (65.2) 5.966 (2.233-15.90)** 5.629 (2.071-15.30)** 6.397 (2.177-18.79)**
P for trend = 0.002 P for trend = 0.002 P for trend< 0.001
†OR adjusted for age and body mass index.
{OR adjusted for age, body mass index, habitual alcohol consumption, coffee consumption and antihypertensive medication.
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dehydrogense ROS production is significantly lower in
Mt4738A genotypic mice than in Mt4738C genotypic mice
[30]. Extrapolation from experimental mice to human may
assume that ND2-237Met suppresses ROS production.
Moreover, deliberating on that methionine residues play an
antioxidant role in scavenging ROS [31], ND2-237Met may
also protect NADH dehydrogenase itself and mitochondrial
DNA from ROS. Cigarette smoke contains high concentra-
tions of ROS, and is supposed to activate endogenous
sources of ROS [4]. There may be biophysical and bio-
chemical differences in the protection against cigarette
smoking-induced ROS or the reduction of cigarette
smoking-induced ROS generation between ND2-237Leu
and ND2-237Met. These deduced differences are conjec-
tured to bring that Mt5178 C/A polymorphism modifies
the effects of cigarette smoking on the risk of hypo-HDL
cholesteloremia, hyper-LDL cholesterolemia or hypertri-
glyceridemia. We cannot prepare either satisfactory eluci-
dation to the discrepancy between combined effects of
Mt5178A genotype and cigarette smoking on serum LDL
cholesterol levels and those on the risk of hyper-LDL cho-
lesterolemia. Considering that mitochondrial DNA is ma-
ternally inherited, a possibility is speculated that there is a
genetic linkage between Mt5178A genotype and the other
mitochondrial DNA genotype affecting the risk of hyper-
LDL cholesterolemia. Anyway, in order to reveal the
mechanisms responsible for interaction between ND2-237
Leu/Met genotypes and habitual smoking on the risk of
dyslipidemia, further molecular biochemical and pharma-
cological inquiries are required.
In interpreting our results, it is necessary to con-
template the validity of the study design. The lifestyle
habits, especially diet, probably vary between smokers
and non-smokers. Systematic reviews manifest the
effects of diets on serum lipids levels [32,33]. Hence,
diet survey is required. The study sample size was
not sufficient to test the gene-environment inter-
action. Chi-squared test does not show a significant
statistical difference in the frequency of Mt5178A be-
tween in this study and in the large-scale molecular
epidemiological survey [34], thus suggesting that
there is no critical genetic bias in the subjects in this
study. However, we cannot deny selection bias due to
selection of subjects from those visiting the hospital
for regular medical check-ups. Based on the cross-
sectional as well as longitudinal study, Kuzuya et al.
speculated that the effects of habitual smoking on
serum lipid levels are influenced by age [6]. Add-
itional-ly, although cross-sectional studies can con-
tribute suggestive causal links, they cannot establish a
valid causality. Therefore, in order to conquer these
limitations denoted above, a large-scale population-
based follow-up study is necessary.In conclusion, longevity-associated Mt5178 C/A poly-
morphism may modulate the effects of habitual smoking
on the risk of dyslipidemia in middle-aged Japanese
men. For Mt5178A genotypic men, cigarette smoking
may increase the risk of hyper-LDL cholesterolemia or
that of hypertriglyceridemia and may squander their
genetic resistance against atherosclerosis. On the other
hand, for Mt5178C genotypic men, habitual smoking
may increase the risk of hypo-HDL cholesterolemia and
may coerce them more susceptible to subsequent
atherosclerotic diseases. Genetic information of Mt5178
C/A polymorphism may propose the personalized be-
havioral modification for controlling of dyslipidemia,
thereby clinically reducing the incidence of CHD. More-
over, this new gene-environmental interaction may con-
tribute to elucidation of molecular pathophysiology of
smoking- or mitochondria-related atherogenesis.
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